Developmental and Molecular Effects of C-Type Natriuretic Peptide Supplementation in In Vitro Culture of Bovine Embryos

被引:0
|
作者
Costa, Camila Bortoliero [1 ,2 ,3 ]
da Silva, Nathalia Covre [3 ]
Silva, Amanda Nespolo [4 ,5 ]
Pioltine, Elisa Mariano [2 ]
Dellaqua, Thaisy Tino [1 ]
Zangirolamo, Amanda Fonseca [3 ,6 ]
Meirelles, Flavio Vieira [5 ]
Seneda, Marcelo Marcondes [3 ,6 ]
Nogueira, Marcelo Fabio Gouveia [1 ,2 ]
机构
[1] Sao Paulo State Univ UNESP, Inst Biosci, Grad Program Pharmacol & Biotechnol, BR-18618970 Botucatu, SP, Brazil
[2] Sao Paulo State Univ UNESP, Sch Sci Humanities & Languages, Dept Biol Sci, BR-19806900 Assis, SP, Brazil
[3] Univ Londrina UEL, Dept Vet Med, Lab Anim Reprod, BR-86057970 Londrina, PR, Brazil
[4] Univ Sao Paulo, Grad Program Anat Domest & Wild Anim, BR-13635000 Pirassununga, SP, Brazil
[5] Univ Sao Paulo, Coll Anim Sci & Food Engn, Dept Vet Med, BR-13635000 Pirassununga, SP, Brazil
[6] Univ Londrina UEL, Natl Inst Sci & Technol Dairy Prod Chain INCT LEIT, BR-86057970 Londrina, PR, Brazil
基金
巴西圣保罗研究基金会;
关键词
C-type natriuretic peptide; embryonic metabolism; NPR2; transcript abundance; cattle; ENDOPLASMIC-RETICULUM; COMPETENCE; EXPRESSION; COMPLEXES; OOCYTES; GENE; IVM;
D O I
10.3390/ijms252010938
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The use of C-type natriuretic peptide (CNP) in the interaction with the oocyte and in the temporary postponement of spontaneous meiosis resumption has already been well described. However, its action in pre-implantation developmental-stage embryos is yet to be understood. Thus, our study aimed to detect the presence of the canonical CNP receptor (natriuretic peptide receptor, NPR2) in germinal vesicle (GV)-, metaphase II (MII)-, presumptive zygote (PZ)-, morula (MO)-, and blastocyst (BL)-stage embryos and, later, to observe possible modulations on the embryos when co-cultured with CNP. In Experiment I, we detected and quantified NPR2 on the abovementioned embryo stages. Further, in Experiment II, we intended to test different concentrations (100, 200, or 400 nM of CNP) at different times of inclusion in the in vitro culture (IVC; inclusion from the beginning, i.e., day 1, or from day 5). In Experiment III, 400 nM of CNP was used on day 1 (D1) in the IVC, which was not demonstrated to be embryotoxic, and it showed potentially promising results in the blastocyst production rate when compared to the control. Thus, we analyzed the embryonic development rates of bovine embryos (D7) and hatching kinetics (D7, D8, and D9). Subsequently, morula and blastocyst were collected and evaluated for transcript abundance of their competence and quality (apoptosis, oxidative stress, proliferation, and differentiation) and lipid metabolism. Differences with probabilities less than p < 0.05, and/or fold change (FC) > 1.5, were considered significant. We demonstrate the presence of NPR2 until the blastocyst development stage, when there was a significant decrease in membrane receptors. There was no statistical difference in the production rate after co-culture with 400 nM CNP. However, when we evaluated the abundance of morula transcripts, there was an upregulated transcription in ADCY6 (p = 0.057) and downregulated transcripts in BMP15 (p = 0.013), ACAT1 (p = 0.040), and CASP3 (p = 0.082). In addition, there was a total of 12 transcriptions in morula that presented variation FC > 1.5. In blastocysts, the treatment with CNP induced upregulation in BID, CASP3, SOX2, and HSPA5 transcripts and downregulation in BDNF, NLRP5, ELOVL1, ELOVL4, IGFBP4, and FDX1 transcripts (FC > 1.5). Thus, our study identified and quantified the presence of NPR2 in bovine pre-implantation embryos. Furthermore, 400 nM of CNP in IVC, a concentration not previously described in the literature, modulated some transcripts related to embryonic metabolism, and this was not embryotoxic morphologically.
引用
收藏
页数:15
相关论文
共 50 条
  • [31] C-Type Natriuretic Peptide and Cardiac Fibrosis
    Richards, A. Mark
    HYPERTENSION, 2011, 57 (02) : 154 - 155
  • [32] Regulation of C-type natriuretic peptide expression
    Sellitti, Donald F.
    Koles, Nancy
    Mendonca, Maria C.
    PEPTIDES, 2011, 32 (09) : 1964 - 1971
  • [33] C-type natriuretic peptide in prostate cancer
    Nielsen, Soeren Junge
    Iversen, Peter
    Rehfeld, Jens F.
    Jensen, Helle Lone
    Goetze, Jens Peter
    APMIS, 2009, 117 (01) : 60 - 67
  • [34] C-type natriuretic peptide and heart failure
    Del Ry, Silvia
    Passino, Claudio
    Emdin, Michele
    Giannessi, Daniela
    PHARMACOLOGICAL RESEARCH, 2006, 54 (05) : 326 - 333
  • [35] C-type natriuretic peptide in childhood obesity
    Cabiati, Manuela
    Sgalippa, Agnese
    Federico, Giovanni
    Del Ry, Silvia
    PEPTIDES, 2021, 145
  • [36] C-type natriuretic peptide is produced by the kidneys
    Kalra, PR
    Clague, JR
    Bolger, A
    Sharma, R
    Anker, SD
    Poole-Wilson, PA
    Coats, AJ
    Struthers, AD
    EUROPEAN HEART JOURNAL, 2004, 25 : 651 - 651
  • [37] C-TYPE NATRIURETIC PEPTIDE IS A POTENT VENODILATOR
    WEI, CM
    AARHUS, LL
    MILLER, VM
    BURNETT, JC
    CIRCULATION, 1992, 86 (04) : 219 - 219
  • [38] THE IN-VITRO ACTIONS OF C-TYPE NATRIURETIC PEPTIDE IN CORONARY-ARTERIES
    WEI, CM
    HU, SL
    KIM, CH
    MILLER, V
    BURNETT, JC
    CIRCULATION, 1993, 88 (04) : 181 - 181
  • [39] Vasodilator effects of C-type natriuretic peptide on cerebral arterioles in rats
    Mori, Y
    Takayasu, M
    Suzuki, Y
    Shibuya, M
    Yoshida, J
    Hidaka, H
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 320 (2-3) : 183 - 186
  • [40] Acute hypertonicity attenuates cardiac effects of C-type natriuretic peptide
    Cho, KW
    Quan, HX
    Jin, X
    Kim, SZ
    Kim, SH
    Lee, HS
    FASEB JOURNAL, 2005, 19 (04): : A558 - A558